Immunogenicity of Protein Therapeutics: Therapeutic proteins are susceptible to aggregation in response to a wide variety of stresses encountered during their manufacture, storage and delivery to ...

Understanding these mechanisms opens new avenues for therapeutic strategies aimed at halting or slowing disease progression by targeting the spread of protein aggregates. The research team is ...

mRNA therapies are one of the hottest drug classes today, but scientists need to solve issues of stability, immunogenicity ... to produce therapeutic or antigenic proteins, these molecules promise ...

Researchers at Ruhr University Bochum discovered that a lipid anchor on nerve cell membranes stabilizes prion protein folding, preventing harmful aggregation linked to prion diseases. Their in vitro ...

fusion proteins and multi-specifics. These are likely to dominate the future antibody therapeutic market, but many of them express poorly and have aggregation issues leading to delays to projects.

The new treatment would target the harmful build-up of proteins in ... the delivery of therapeutic antibodies but also enhances their efficacy in clearing tau aggregates and improving cognitive ...